March is not only Autoimmune Awareness Month but also Women's History Month! These two celebrations occurring at the same time should be no surprise, especially since women are at a higher risk of developing autoimmune diseases compared to men.

Individuals diagnosed with an autoimmune disease may have heard of “multiple autoimmune syndrome.” Multiple autoimmune syndrome (MAS) is defined as a patient having at least three autoimmune diseases.

Rare Disease Day, observed every February 28th, is dedicated to raising awareness about the challenges faced by individuals living with rare diseases.

Diversity isn't just a buzzword when researching autoimmune and rare diseases—it’s essential for better treatments and care. These conditions affect people from all backgrounds, but clinical trials often don’t reflect that diversity.

Current treatments for autoimmune diseases mostly consist of drugs that suppress the immune system and can lead to undesirable side effects. However, a new study shows that vagus nerve stimulation—which consists of tiny pulses of electricity that stimulate the vagus nerve—may offer an innovative way to replace drug treatments.

A study published by the Journal of Investigative Dermatology reveals a potential breakthrough treatment for those diagnosed with vitiligo.

Last year, we discussed how artificial intelligence (AI) could be used to enhance autoimmune disease prediction and treatments through an algorithm called EXPRESSO—EXpression PREdiction with Summary Statistics Only—developed by a research team at Penn State College of Medicine. Penn State researchers have developed a new AI method to predict autoimmune disease progression.

Psoriasis is known to be a chronic skin condition, but it can also result in inflammation of the joints. Previous research also shows that Crohn's disease is one of the top comorbidities in psoriasis patients, but the reasoning behind this was unknown. However, new research at Uppsala University in Sweden could explain why those diagnosed with psoriasis are more prone to gastrointestinal problems.

The University of Toledo's College of Medicine and Life Sciences has made a groundbreaking discovery regarding the treatment of rheumatoid arthritis (RA), a possible treatment that helps suppress inflammatory cells while increasing anti-inflammatory responses.

Working with data from the National Institutes of Health’s (NIH’s) All of Us Program, the Autoimmune Registry aims to transform how patients with autoimmune diseases understand and manage their health, providing them with critical insights that could lead to more personalized care and improved health outcomes.

This year, the Autoimmune Registry has continued to work towards reducing the time of diagnosis, supporting autoimmune research, computing prevalence statistics, and establishing autoimmune disease as a major disease class.

Autoimmune diseases can arise from a combination of genetic factors and environmental triggers. Increasingly, research has focused on the role of environmental exposures, particularly air pollution, in developing these conditions.

Researchers hypothesized that there may be a hereditary risk for autoimmune diseases in women with primary ovarian insufficiency (POI). A recent study in The Journal of Clinical Endocrinology & Metabolism examined the link between autoimmune diseases and POI using the electronic health records of 610 women diagnosed with POI as well as their close relatives.

Receiving a misdiagnosis or having symptoms dismissed by healthcare providers are common experiences for people with autoimmune diseases.

Last year, we discussed how those diagnosed with vitiligo have a higher chance of having another autoimmune disease. However, recent research shows that there may be a correlation between vitiligo and hearing loss.

Our mission at the Autoimmune Registry is to establish autoimmune disease as a major class of disease through supporting research in hopes of reducing the time of diagnosis, gaining the attention of healthcare providers, and improving existing treatment protocols.

Based on a mouse model study, researchers at Emory University reveal a family of enzymes, particularly one called CU43, that can reduce the impact of these harmful antibodies in diseases like MG.